Last reviewed · How we verify

NCT06171048

Study Evaluating the Pharmacokinetics of CM310 in Healthy Subjects

Status unknown Phase 1 Last updated 14 December 2023
What this trial tests

Phase 1 trial testing CM310 in Healthy in 236 participants. Status unknown.

Timeline
30 April 2024
Primary endpoint
30 April 2025
30 April 2025

Quick facts

Lead sponsorKeymed Biosciences Co.Ltd
PhasePhase 1
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment236
Start date30 April 2024
Primary completion30 April 2025
Estimated completion30 April 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Keymed Biosciences Co.Ltd — full company profile →

Who can join

Adults 20 to 45, male only, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-center, randomized, open-label study to evaluate the pharmacokinetics of CM310 in healthy subjects.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of CM310

Trials testing the same drug.

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other Keymed Biosciences Co.Ltd trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06171048.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing